Burden of illness and quality of life in patients being treated for seasonal allergic rhinitis: a cohort survey by Mark Small et al.
Small et al. Clinical and Translational Allergy 2013, 3:33
http://www.ctajournal.com/content/3/1/33RESEARCH Open AccessBurden of illness and quality of life in patients
being treated for seasonal allergic rhinitis: a
cohort survey
Mark Small1, James Piercy1, Pascal Demoly2 and Helen Marsden3*Abstract
Background: Allergic Rhinitis is an inflammatory disease which is characterised by burdensome nasal and/or ocular
symptoms. This study aimed to assess the impact of symptoms (number of symptom-free days (SFD) and Quality of
Life (QoL)) in patients with Seasonal Allergic Rhinitis (SAR) being treated with fluticasone furoate (FF), mometasone
furoate (MF) or fluticasone propionate (FP).
Methods: In a cross-sectional, non-interventional, cohort analysis, primary care physicians and allergy specialists in
France, Germany, and Spain were recruited via telephone interviews. Each physician prospectively recruited 4 SAR
patients - 2 receiving FF, 1 receiving MF and 1 receiving FP - during June 2009. Patients answered questions on
symptoms and completed questionnaires on QoL (mini-rhinoconjunctivitis Quality of Life Questionnaire, RQLQ) and
burden of illness (Pittsburgh Sleep Quality Index).
Results: A total of 540 patients were recruited during June 2009. 88 patients were subsequently found to be
ineligible and excluded from the analyses. In the 4 weeks prior to assessment, patients reported a mean of 14.58
(±8.42) SFD. Patients receiving FF had more SFD (mean 15.45 ±8.29) than patients receiving MF (adjusted mean
difference -1.22, 95% Confidence Interval (CI) [-3.16 to 0.72], p=0.434) or FP (adjusted mean difference -1.95, 95% CI
[-3.87 to -0.03], p=0.092), although statistical significance was not achieved. The mean RQLQ score was 1.54 (±1.06).
Patients receiving FF had a better quality of life in the previous week (mini-RQLQ score: mean 1.42, ±1.04) than
patients receiving MF (adjusted mean difference 0.28, 95% CI [0.03 to 0.52], p=0.052) or FP (adjusted mean
difference 0.18, 95% CI [-0.05 to 0.41], p=0.244). Again, none of these results achieved statistical significance.
Conclusions: At the height of the allergy season, patients with SAR suffer symptoms approximately 50% of the time, and
report an impact on their QoL. No significant differences were observed between FF, FP and MF related to SFD or QoL.
Trial registration: ClinicalTrials.gov identifier: NCT01199757
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Allergic rhinitis (AR) is a common inflammatory condi-
tion of the upper respiratory tract, nasal cavity and eyes af-
fecting up to 20% of the population in the United States
(US) and Europe [1]. AR is characterized by both nasal
and ocular symptoms including rhinorrhoea, sneezing,
itchy/blocked nose, sinus pressure, itchy/red eyes, snoring
and other sleep problems. Across Europe up to 71% of AR
patients suffer from both nasal and ocular symptoms [2],* Correspondence: Helen.c.marsden@gsk.com
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reproduction in any medium, provided the orespecially (but not only) those having seasonal AR (SAR)
and one in five of these (21%) indicated that this was their
most bothersome symptom [2].
The bothersome nature of AR symptoms can severely
affect daily activities including ability to work [3], examin-
ation performance [4,5], impact on Quality of Life (QoL)
and psychosocial well being [6,7]. Patients report that ocu-
lar symptoms are both troublesome [8] and often inad-
equately controlled [2] and it has been demonstrated that
the added presence of ocular symptoms in AR patients
suffering with nasal symptoms deteriorates patients’ QoL,
leads to greater loss of productivity and places highertd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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predominantly during the pollen season, limiting the win-
dow during which the impact of the disease and the effect
of treatment can be assessed.
Intranasal corticosteroids (INS) have been shown to de-
crease ocular symptoms associated with AR as well as
nasal symptoms [10-12]. Similarly, non-sedating antihista-
mines have been shown to be effective at controlling ocular
symptoms of AR patients [13]. Comparative research indi-
cates that INSs provide equal or greater relief of ocular
allergy symptoms compared with intranasal or oral antihis-
tamines [14]. However, antihistamines generally have their
greatest efficacy against early-phase, histamine-mediated
symptoms (e.g. itching, rhinorrhoea) and lesser efficacy in
treating late phase symptoms (e.g. congestion) [11]. Recent
patient preference studies have shown that patients have
high expectations of their anti-allergic treatment, desiring
attributes such as good symptom relief, quick-onset and
long-lasting effects and favourable side effect profile
[15,16]. However, patients are often dissatisfied with the ef-
ficacy of their treatment which can lead to poor compli-
ance and supplementation with over the counter products
[16]. A study of patients under specialist care reported that
patients preferred nasal spray to oral treatment, however
feared adverse events (such as habituation, damage to mu-
cous membranes, addiction and influence on other organs)
of INS therapies [15]. This data highlights the need for INS
treatments to have good all round efficacy, with a reassur-
ing safety profile, to provide a holistic treatment for AR
that improve the patients’ quality of life.
Several studies of INS treatments have looked at their
impact on quality of life [17-21]. INS therapies have gener-
ally been reported to have a clinically meaningful improve-
ment in QoL, as measured by the Rhinoconjunctivitis
Quality of Life Questionnaire, compared to placebo. How-
ever few studies have compared the impact of different
INS therapies on symptoms and quality of life.
Here we report the results of a real world survey of
treated SAR patients focusing on the occurrence of
Symptom-free days (SFD) over the previous 4 weeks and
quality of life over the previous week, and comparing
three commonly used INS treatments. The study also
looked at the impact of INS therapies on: work product-
ivity, sleep, visits to health care professionals and out of
pocket expenditure on over the counter medications.
Methods
This was a cross-sectional, non-interventional, cohort sur-
vey analysis, conducted in June 2009 conducted by Adelphi
Real World. ClinicalTrials.gov identifier: NCT01199757.
A random sample of 30 Primary Care Physicians (PCPs)
and 15 allergy specialists in France, Germany, and Spain
were recruited via telephone interviews by local agencies.
To maximise generalisability, our physician recruitmentcriteria were as broad as possible so to not limit our pri-
mary care physician population to those who specialised
in allergy. The only inclusion criteria were that each phys-
ician had to have qualified after 1970, see three or more
AR patients per week, be personally responsible for treat-
ment decisions for their AR patients and agree to
participate.
Each physician prospectively recruited four consecutive
consulting SAR patients over the age of 12 who were re-
ceiving, and had received at least one full prescription of,
specified INS therapy and who agreed to participate in
the research. Patients with a co-diagnosis of asthma or
Chronic Obstructive Pulmonary Disease (COPD) were ex-
cluded. Two patients receiving FF [Avamys™], one patient
receiving mometasone furoate (MF) [Nasonex™] and one
patient receiving fluticasone propionate (FP) [Flixotide™]
were recruited (in any order) by each physician. The sur-
vey was conducted as research in accordance with and de-
fined by the European Pharmaceutical Market Research
Association (EphMRA) code of conduct for international
healthcare market research, so ethical approvals were not
required. In line with EphMRA requirements, all partici-
pating patients provided informed consent. No tests or in-
vestigations were performed as part of this research, and
to ensure compliance with data protection laws, all data
were de-identified and aggregated prior to receipt by
Adelphi Real World.
Physicians recorded data relating to patient characteris-
tics including demographics, disease classification as de-
fined by the ARIA (Allergic Rhinitis and its Impact on
Asthma) guidelines [22], symptoms, patient visits, INS
treatment (including whether for ocular and/or nasal
symptoms) and co-prescription. Physicians were asked to
capture this information by ticking a pre-coded list. The
provided information was based on the assessment by the
physician whether this be from the most recent consult-
ation or with recourse to patient notes.
Each patient was asked to complete a matched patient-
completion forms independent from the physician on
symptoms over the previous 4 weeks, and QoL and burden
of illness questionnaires: mini-rhinoconjunctivitis Quality
of Life Questionnaire (RQLQ), Pittsburgh Sleep Quality
Index (PSQI), Work Productivity and Activity Impairment:
Allergy Specific questionnaire plus Classroom Impairment
Questions: Allergy Specific (WPAI+CIQ:AS). The number
of work days lost, PCP or specialist visits due to AR, and
over-the-counter (OTC) medicines used over the previous
4 weeks were also recorded.
The mini-RQLQ [23] assesses QoL over the previous
week. It is comprised of 14 items, in five domains (Ac-
tivity Limitations, Practical Problems, Nose Symptoms,
Eye Symptoms and Other Symptoms), each evaluated
on a seven point scale (0 = “Not troubled”, 6 =“Ex-
tremely troubled”). The overall QoL score is the mean
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Difference is 0.7.
The PSQI [24] assesses sleep quality and disturbance
over the previous month. It is split into seven compo-
nents: Subjective sleep quality; Sleep latency; Sleep dur-
ation; Habitual sleep efficiency; Sleep disturbance; Use
of sleep medication; Daytime dysfunction. Each compo-
nent score ranges from 0 (no difficulty) to 3 (severe dif-
ficulty). The final PSQI global score is derived from
summing these seven component scores (range 0 to
21). A score of >5 is suggestive of significant sleep dis-
turbance, but no minimally important difference has
been reported.
The WPAI+CIQ:AS [25] assesses work, classroom and
activity impairment over the previous seven days. This has
nine questions which form three domains (work for work-
ing people, study for students and activity impairment for
both subgroups). Seven separate ‘scores’ are produced
which related to: Percent work time missed due to allergy;
Percent impairment while working due to allergy; Percent
overall work impairment due to allergy; Percent class time
missed due to allergy; Percent impairment in the class-
room due to allergy; Percent regular activity (other than
work or classes) impairment due to allergy.
Each patient was asked how much they had spent (in
Euros) on medication for their AR from a pharmacy or
supermarket that had not been prescribed by their doc-
tor between over the previous 3 months.
The sample size was chosen based on the practicalities
of conducting the study, and was designed to ensure a
spread of patients across both primary care and special-
ist care, and between the therapies of interest. No formal
sample size or power calculations were made. The 2:1:1
ratio was chosen to collect a higher number of patients
on FF as it was planned to compare FF against MP and
FP both separately and combined. Please note that only
patients who were already receiving these medications
were included, therefore there was no possibility for
physicians to initiate treatment of any kind in order to
include patients in the study.
Ordinary Least Square (OLS) regression models were
used on the following outcome variables: number of
SFD over the past four weeks, mini-RQLQ, PSQI,
WPAI+CIQ:AS, number of work days lost, number of
healthcare professional (HCP) consultations (physician
reported), number of HCP consultations (patient
reported), number of AR treatments, number of OTC
products used and total OTC spend. Variables such as
age, gender, Body Mass Index (BMI), number of con-
comitant conditions since March 2009, number of AR
drugs currently prescribed and ARIA severity were in-
cluded in the model to control for any influence they
may have had on the results of generic assessments
such as time off work, and overall health status.All analyses were conducted on the total study popula-
tion, and by country, ARIA severity Bonferroni corrections
were made for the multiple comparisons but no adjust-
ments were made for missing data; results presented are
based on available data only. All statistical analyses were
conducted in Stata Version 10.1.
A post-hoc analysis on a sub-group of patients who
had experienced both ocular and nasal symptoms was
conducted. Nasal and ocular patients were defined as
those who had ever suffered with itchy/red eyes and/or
watery eyes in addition to having nasal symptoms (as de-
fined by the symptoms provided by the physician).
Results
Population
540 SAR patients were recruited into the study. Subse-
quently 88 patients were found to be on more than one
INS, and were excluded from the analyses. The study
population, where demographic information was available,
was 52.2% female, had a mean age of 36.2 (±13.9) years,
and had a mean BMI of 24.1 (±3.7), which was compar-
able across the INS groups (Table 1). Our study popula-
tion was made up of mostly (54.5%) moderate/severe
persistent patients, with only a few (12.2%) mild intermit-
tent patients. The mean number of co-morbidities
reported during the study period was 0.96 (±1.14), and the
mean number of concomitant medications taken in the
same period was 1.60 (±0.67) - both of which were similar
across the treatment groups.
Symptom-free days
The mean number of SFD over the previous 4 weeks
reported by the 417 patients that answered this question
was 14.58 (±8.42) days. Patients receiving FF were associ-
ated with having more SFD (mean 15.45 ±8.29) than pa-
tients receiving MF (adjusted mean difference −1.22, 95%
Confidence Interval (CI) [−3.16 to 0.72], p=0.434) or FP
(adjusted mean difference −1.95, 95% CI [−3.87 to −0.03],
p=0.092), although statistical significance was not achieved
(Table 2; Figure 1).
When analyzed by country and ARIA severity, patients
on FP reported fewer SFD in all the sub-groups, though
none reached statistical significance. Similarly most of the
sub-groups of patients receiving MF reported fewer SFD,
except Spanish and moderately severe, intermittent sub-
groups which were associated with greater SFD. Again,
none of these reached statistical significance (Table 2).
Quality of life
The mean mini-RQLQ score reported by the 429 patients
that completed the questionnaire was 1.54 (±1.06). Pa-
tients receiving FF were associated with having a better
quality of life in the previous week (mini-RQLQ score:
mean 1.42, ±1.04) than patients receiving MF (adjusted
Table 1 Patient population characteristics
Total FF MF FP
N=452 N=229 N=108 N=115
Age (Mean, (SD)) 36.2 (13.9) 36.5 (13.7) 35.8 (13.7) 36.1 (14.6)
Gender (% females) 52.2% 49.8% 53.7% 55.7%
Body mass index (Mean, (SD)) 24.1 (3.7) 24.1 (3.8) 24.3 (3.9) 23.9 (3.5)
Country of origin (N, %):
France 163 (36.1%) 82 (35.8%) 38 (35.2%) 43 (37.4%)
Germany 174 (38.5%) 88 (38.4%) 43 (39.8%) 43 (37.4%)
Spain 115 (25.4%) 59 (25.8%) 27 (25.0%) 29 (25.2%)
ARIA severity (N, %):
Mild intermittent 54 (12.2%) 29 (12.9%) 10 (9.6%) 15 (13.2%)
Moderate/severe intermittent 147 (33.3%) 81 (36.2%) 38 (36.5%) 28 (24.6%)
Moderate/severe persistent 241 (54.5%) 114 (50.9%) 56 (53.8%) 71 (62.3%)
Number of concomitant conditions reported in the previous 3 months (mean, SD) 0.96 (1.14) 0.96 (1.07) 1.00 (1.25) 0.92 (1.16)
Number of concomitant medications taken in the previous 3 months (mean, SD) 1.60 (0.67) 1.61 (0.67) 1.57 (0.61) 1.60 (0.74)
Number of patients who ever experienced both ocular and nasal symptoms (N, %) 324 (71.7%) 162 (70.7%) 81 (75.0%) 81 (70.4%)
FF: Fluticasone furoate; FP: Fluticasone propionate; MF: Mometasone furoate; SD: Standard Deviation; N: Number of patients.
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FP (adjusted mean difference 0.18, 95% CI [−0.05 to 0.41],
p=0.244) Again, none of these results achieved statistical
significance (Table 3; Figure 2).
When analyzed by country and ARIA severity, patients
on FF reported a better RQLQ score compared to MF or
FP in all sub-groups except in mild intermittent patients.
Only the lower RQLQ score for FF compared to MF in
French patients (+0.46) and moderately severe persistent
patients (+0.45) reached statistical significance (Table 3).
Other analyses
In a post-hoc analysis on those SAR patients (N=324,
71.6%) who had ever experienced both ocular and nasal
symptoms, the mean number of SFD was fewer than in
the overall study population (14.51 ±8.23). InterestinglyTable 2 Symptom free days by country and ARIA severity
Total FF
N Mean (SD) N Mean (SD
Symptom-free days 417 14.58 (8.42) 208 15.45 (8.2
Country sub-groups
France 152 14.45 (8.74) 75 16.15 (8.4
Germany 165 16.19 (7.70) 83 16.45 (7.7
Spain 100 12.12 (8.51) 50 12.74 (8.5
Severity sub-groups
Mild intermittent 50 18.72 (8.34) 26 20.23 (7.6
Moderate/severe intermittent 138 15.21 (7.57) 74 15.05 (7.4
Moderate/severe persistent 229 13.30 (8.62) 108 14.56 (8.6
FF: Fluticasone furoate; FP: Fluticasone propionate; MF: Mometasone furoate; β = adthose patients receiving FP and MF reported fewer SFD
than the overall group of patients on these therapies, while
patients receiving FF reported a greater number of SFD
than the overall group receiving FF (Figures 1 and 3). Pa-
tients in this sub-population who were receiving FF were
associated with more SFD than FP (adjusted mean differ-
ence −2.34, 95% CI [−4.60 to −0.09], p=0.084) and MF
(adjusted mean difference 2.90, 95% CI [−5.13 to −0.67],
p=0.022). Similarly, patients in this sub-population, and
on each therapy, reported worse RQLQ scores than the
overall study population (data not shown). Patients on FF
reported better QoL than those patients on FP (adjusted
mean difference 0.24, 95% CI [−0.04 to 0.52], p=0.184) or
MF (adjusted mean difference 0.28, 95% CI [−0.01 to
0.57], p=0.110), but neither of these were statistically
significant.MF FP
) N β 95% CI N β 95% CI
9) 102 −1.22 −3.16 to 0.72 107 −1.95 −3.87 to −0.03
3) 36 −3.03 −6.37 to 0.32 41 −2.77 −6.03 to 0.49
4) 42 −0.81 −3.68 to 2.07 40 −0.59 −3.50 to 2.33
1) 24 1.48 −2.56 to 5.53 26 −0.98 −4.99 to 3.03
9) 9 −1.77 −9.12 to 5.58 15 −2.30 −8.68 to 4.08
9) 38 1.44 −1.57 to 4.46 26 −1.76 −5.23 to 1.70
2) 55 −2.50 −5.29 to 0.28 66 −1.95 −4.58 to 0.69
justed mean difference from FF.
Figure 1 Number of symptom free days in the past 4 weeks for
patients on each INS therapy. FF: Fluticasone furoate; FP:
Fluticasone propionate; MF: Mometasone furoate; INS:
intranasal corticosteroids.
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naire reported a mean score of 4.25 (±3.00), which indi-
cates that the majority of responders were not suffering
from significant sleep disturbance. In contrast, the mean
WPAI scores indicate that allergy was impairing patients’
school or work activities, and mean number of work
days lost in the previous 3 months due to allergy was
0.78 (±3.12) (Table 4). Patients reported visiting their
primary care physician and specialist physicians in the
previous 3 months a mean of 2.06 (±1.72) and 0.96
(±1.37) times, respectively. However, physicians reported
a higher visit rate to both the primary care physiciansTable 3 mini-RQLQ scores by country and ARIA severity
Total FF
N Mean (SD) N Mean (S
Mini-RQLQ score 429 1.54 (1.06) 217 1.42 (1.0
Country sub-groups:
France 155 1.35 (0.98) 79 1.25 (1.0
Germany 170 1.57 (0.97) 86 1.48 (0.9
Spain 104 1.75 (1.27) 52 1.57 (1.1
Severity sub-groups:
Mild intermittent 52 0.89 (0.80) 28 0.92 (0.8
Moderate/severe intermittent 143 1.41 (0.98) 78 1.35 (1.0
Moderate/severe persistent 234 1.76 (1.09) 111 1.59 (1.0
FF: Fluticasone furoate; FP: Fluticasone propionate; MF: Mometasone furoate; β = ad
*p<0.05 (Bonferroni correction applied).(mean 2.22 ±1.04 visits) and specialists (mean 2.28 ±1.32
times).
Patients on FF reported a better PSQI score than ei-
ther FP or MF and generally reported less overall impact
on work and classroom impairment, except percent
work time missed and impairment in the classroom due
to allergy. Additionally, patients receiving FF reported
fewer work days lost in the previous three months, and
fewer patient- or physician-reported visits to PCPs or
specialists, than for FP or MF (Table 4). Less OTC drugs
were used by patients on FF over the previous 3 months
than FP (p<0.05) or MF. However when this was trans-
lated into cost spent on OTC products during that time,
patients receiving FP only spent €1.50 more, and those
receiving MF spent €0.79 less, than patients receiving
FF.
Discussion
Our study demonstrates the impact of allergic rhinitis
on symptoms and quality of life in SAR patients who are
being treated with INS. The mean number of symptom
free days in the overall population was higher than has
been previously reported [2,26] for AR patients, indicat-
ing that these three treatments provide additional relief
from AR symptoms for patients. Similarly the mean
RQLQ scores were generally less than has been reported
previously in AR patients, particularly those with moder-
ate/severe disease [2,23]. However, at the height of the
pollen season, patients still suffer from symptoms nearly
1 in every 2 days, with moderate/severe patients suffer-
ing more than mild patients.
Not achieving statistical significance for the majority
of comparisons between FF and FP or MF obviously
weakens any conclusions that can be drawn as to super-
iority of any one INS product, and we therefore apply
caution in the interpretation of the results presented. FF
was associated with more SFD and a better RQLQ than
FP or MF. A difference of nearly two days of SFD in aMF FP
D) N β 95% CI N β 95% CI
4) 98 0.28 0.03 to 0.52 114 0.18 −0.05 to 0.41
2) 33 0.46 0.09 to 0.83* 43 0.13 −0.22 to 0.48
8) 42 0.12 −0.25 to 0.48 42 0.17 −0.20 to 0.54
6) 23 0.08 −0.51 to 0.66 29 0.06 −0.50 to 0.63
9) 9 −0.01 −0.71 to 0.69 15 −0.21 −0.83 to 0.40
1) 37 0.09 −0.28 to 0.46 28 0.24 −0.18 to 0.65
6) 52 0.45 0.09 to 0.81* 71 0.22 −0.11 to 0.55
justed mean difference from FF.
Figure 3 Symptom free days in patients with both nasal and
ocular symptoms. Number of symptom free days in the past
4 weeks, in patients with a history of both ocular and nasal
symptoms on each INS therapy. FF: Fluticasone furoate; FP:
Fluticasone propionate; MF: Mometasone furoate; INS:
intranasal corticosteroids.
Figure 2 Mini-RQLQ score for patients on each INS therapy.
Mini-RQLQ: mini-rhinoconjunctivitis Quality of Life Questionnaire; FF:
Fluticasone furoate; FP: Fluticasone propionate; MF: Mometasone
furoate; INS: intranasal corticosteroids.
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as this equates to two additional days the patient is able
to live an active life. However, the differences in RQLQ
score are unlikely to represent a clinically relevant im-
provement in QoL as the minimally important difference
for the mini-RQLQ is 0.70 [22].
In addition, the inherent variability that occurs within
real world research (compared to the artificial environ-
ment of randomized controlled trials) can make results
from these types of studies appear weak. However, cor-
roborating trends of greater SFD and better QoL of
those patients receiving FF across country and ARIA se-
verity sub-groups provide tentative evidence that differ-
ences may exist.
Patients who reported ever having suffered from both
ocular and nasal symptoms were considered a population
of interest in the light of increasing importance of man-
aging both these conditions in AR patients. As reported
elsewhere, these patients generally report worse symptom
burden and quality of life to the general AR patients [9].
In our population, we observed a drop in the mean num-
ber of reported symptom free days for those patients on
MF and FP, but not for FF. Similarly, the mean RQLQ
scores were higher in these patients compared to the over-
all study population, confirming that patients who suffer
both nasal and ocular symptoms are more burdened by
their disease. Within this group, FF continues to show a
higher number of SFD and QoL compared to FP and MF.No significant differences could be discerned between
patients receiving FF and those receiving either FP or MF
from the secondary outcomes of sleep, work/classroom
productivity questionnaires or visits to healthcare profes-
sionals. There is likely to be significant variability in these
results as patients can have disturbed sleep, not go to work
or visit a healthcare professional for many different rea-
sons which may be difficult to put down solely to their al-
lergic rhinitis. However, it is interesting to note that of the
12 domains assessed, the patients in the FF arm reported
less impact of AR on their lives than FP and MF in all but
4 (FP) and 3 (MF) domains.
To date there have been very few studies directly com-
paring INS regimens in patients with SAR [27], and these
have mostly compared FF with FP. A Japanese study com-
paring 2 weeks of treatment with FF and FP in AR patients
showed FF once daily was non-inferior to FP twice daily in
change in total nasal symptom scores. There were also
similar improvements in rhinoscopy findings, activity of
daily life interference, and patient-rated evaluation of ther-
apy in the FF and FP groups [28]. Similarly, a US patient
preference study showed both FF and FP significantly im-
proved symptoms in adult patients with SAR. Most pa-
tients preferred the sensory attributes of FF to those of FP
after one week of treatment [29]. Finally, in a large US
study on concomitant medications, FF was shown to
Table 4 Secondary outcome measures
Total FF MF FP
N Mean (SD) N Mean (SD) N β CI N β CI
PSQI Overall 370 4.25 (3.00) 183 4.14 (3.14) 87 0.34 −0.37 to 1.06 100 0.08 −0.60 to 0.77
WPAI % work time missed due to allergy 258 1.66 (9.57) 133 2.23 (12.57) 62 −1.31 −4.23 to 1.61 63 −1.10 −4.02 to 1.82
WPAI % impairment while working due to allergy 273 18.06 (16.55) 143 16.99 (16.79) 65 1.33 −3.53 to 6.20 65 3.09 −1.80 to 7.98
WPAI % overall work impairment due to allergy 255 18.93 (18.27) 131 17.88 (19.29) 62 1.67 −3.86 to 7.21 62 2.43 −3.13 to 7.98
WPAI % class time missed due to allergy 55 1.97 (5.99) 27 1.36 (4.09) 16 1.30 −2.80 to 5.40 12 −1.14 −5.98 to 3.70
WPAI % impairment in the classroom due to allergy 61 17.05 (17.16) 31 16.77 (18.51) 16 −5.33 −15.89 to 5.24 14 −0.81 −12.91 to 11.28
WPAI % overall classroom impairment due to allergy 55 17.37 (17.73) 27 16.44 (17.96) 16 −2.96 −14.69 to 8.76 12 1.02 −12.83 to 14.87
WPAI % activity impairment due to allergy 425 20.16 (16.86) 215 18.42 (16.95) 100 3.20 −0.77 to 7.16 110 3.24 −0.62 to 7.09
Number of work days lost in the previous 3 months due to AR 297 0.78 (3.12) 151 0.59 (1.75) 70 0.55 −0.36 to 1.45 76 0.37 −0.51 to 1.25
Number of PCP visits, as reported by patient, in the previous 3 months 436 2.06 (1.72) 220 1.95 (1.36) 102 0.13 −0.27 to 0.53 114 0.23 −0.16 to 0.62
Number of specialist visits as reported by patient, in the previous 3 months 437 0.96 (1.37) 220 0.88 (1.24) 103 0.15 −0.16 to 0.47 114 0.09 −0.21 to 0.40
Number of PCP visits, as reported by physician, in the previous 3 months 283 2.22 (1.04) 144 2.19 (0.98) 66 0.09 −0.21 to 0.38 73 −0.12 −0.40 to 0.17
Number of specialist visits as reported by physician, in the previous 3 months 153 2.28 (1.32) 76 2.16 (1.18) 36 0.37 −0.13 to 0.87 41 0.17 −0.30 to 0.65
Number of non-prescribed (OTC) drugs over the previous 4 weeks 437 0.24 (0.53) 220 0.19 (0.45) 103 0.05 −0.06 to 0.19 114 0.12 0.01 to 0.23*
FF: Fluticasone furoate; FP: Fluticasone propionate; MF: Mometasone furoate; β = adjusted mean difference from FF.
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pared with other leading branded INS therapies, includ-
ing MF and FP [30]. This last study supports some of
the data we present here, where we found patients re-
ceiving FF required significantly fewer non-prescription
(OTC) medications over the previous four weeks than
patients receiving FP.
No direct comparison of the efficacy of INSs on ocular
symptoms exists, but a recent review of available data
highlighted that the data supporting FF consistently showed
positive effects, while conflicting, inconsistent or negative
effects were observed with the other INSs examined [14].
Further studies directly comparing efficacy on nasal and
ocular symptoms, improvement in QoL and patient prefer-
ences of INS regimens and even anti-histamines, in subjects
with AR, are needed.
Limitations
A number of limitations in this study design exist. The
diagnosis of SAR was based on the physicians’ diagnosis
rather than a formalized definition of the condition,
which may have allowed patients who would not have
met a strict definition of SAR of a clinical study to par-
ticipate. Additionally, a patient selection bias may exist
in the study, as the study population represents a con-
venience sample. It is unlikely to be representative of the
overall population of patients with SAR, although it
should be representative of the consulting population.
While studies such as ours focus on a self-selecting sub-
set of SAR patients, it is probable that those patients
who do consult with their PCP are those most bothered
by their symptoms, and therefore represent a population
most in need of effective treatment.
This was a real world design which was reliant on pa-
tients having been sufficiently adherent to their treat-
ment and their recollection of their health over a period
of time. This can introduce recall bias although there
was no reason to assume this would affect one study
population more than another.
As the study was cross-sectional it is not possible to de-
rive a causal relationship between drug and effect, nor do
we know whether patients prescribed FF were originally
more or less burdened by their disease than their counter-
parts who were prescribed FP or MF. Neither did we col-
lect information on time since diagnosis, or time on
treatment, which similarly may have impacted the study re-
sults. However, we are able to infer association whilst tak-
ing into consideration confounding variables to strengthen
conclusions drawn from the associations generated. Add-
itionally, SAR is not considered to be a progressive disease
so current severity evaluation usually acts as a proxy for se-
verity of disease. This study design also does not allow us
to assess any change over time, or investigate whether
these results hold true during periods of high or low pollencounts. A baseline severity may have allowed comparisons
between the treatments to be made between the arms with
more confidence, however a retrospective baseline would
have been subjective and open to interpretation, so it was
not included in the study.
The sample size for the study was based on the practi-
calities of conducting the study, and not on a formal
power calculation or adjusting for multiplicity. In retro-
spect, the sample size may not have been sufficiently
large to allow for statistical investigation of the effects of
the different therapies over a large number of variables.
Given that the main focus was on significant results,
confidence that these results will generalise to independ-
ent data is weaker than if analysis involved a single com-
parison only. However, the totality of our results
provides directional evidence that FF performs better
than either FP or MF across a range of criteria in this
population, which is consistent with the randomised
controlled trial results.
Conclusions
At the height of the allergy season, patients being treated
for SAR still suffer symptoms and report an impact on
their QoL. SAR patients who had ever suffered from ocu-
lar and nasal symptoms, reported fewer SFD and a poorer
QoL than the general SAR population. Directional evi-
dence is presented to show FF is associated with more
SFD and a better QoL than both FP and MF. However, the
absence of statistical significance weakens the strength of
any interpretation other than no key significant differences
were observed between FF, FP and MF.
Abbreviation
AR: Allergic rhinitis; ARIA: Allergic rhinitis and its impact on asthma;
BMI: Body mass index; CI: Confidence interval; COPD: Chronic obstructive
pulmonary disease; EphMRA: European pharmaceutical market research
association; FF: Fluticasone furoate; FP: Fluticasone propionate;
HCP: Healthcare professional; INS: Intranasal corticosteroids; MF: Mometasone
furoate; OLS: Ordinary least square; OTC: Over-the-counter; PCP: Primary care
physician; PSQI: Pittsburgh sleep quality index; QoL: Quality of life;
RQLQ: Mini-rhinoconjunctivitis quality of life questionnaire; SAR: Seasonal
allergic rhinitis; SD: Standard deviation; SFD: Symptom-free days; US: United
States; WPAI+CIQ AS: Work productivity and activity impairment: allergy
specific questionnaire plus classroom impairment questions: allergy specific.
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